I popular therapeutic measure with an increasing number of patients being treated for bronchopulmonary diseases, as well as for the prevention of bronchopulmonary disorders following surgery. A further impetus to inhalational therapy has been the addition of ultrasonic nebulization, which is reported to be capable of delivering large quantities of moisture to the lower tracheobronchial tree, thus enhancing bronchial toiletry. 1- 5 We have observed that many of our patients with chronic obstructive lung disease (COLD) complain bitterly or even refuse inhalational therapy because of accompanying discomfort, especially when ultrasonic therapy is delivered via intermittent positive pressure breathing ( IPPB ) . Studies have shown that artificial fog and ultrasonic nebulization will cause an increase in airway resistance,"s but we were concerned about the blood gas changes, especially in hypoxic patients and whether they were related to symptoms. ' Chief, Medical Service, Veterans Administration Center, Dayton, Ohio; and Clinical Associate Professor of Medicine, Ohio State University College of Medicine, Columbus.
Blood gas data were studied in 20 hospitalized patients who were receiving ultrasonic treatment in the Inhalational Therapy Department. Five patients did not have COLD (group 1). Two of the patients in this group had had acute bronchitis and were asymptomatic at the time of the study. Two were patients with bronchogenic carcinoma, and the fifth ~a t i e n t had rheumatic heart disease with no evidence of lung disease. This heterogenous group was considered as the "control" group. Their baseline ventilatory and gas values are compared with those of the 15 patients with COLD in Table  1 . Fifteen patients had COLD of moderate to very severe degree. Ten of these 15 had normal resting Paco2 (group 2 ) and five (group 3 ) had hypercapnia with P a w values ranging from 49 to 60 mm Hg.
Their pulmonary disease status was stable at the time of the study. Ventilatory measurements of FEV,, M W , RV, TLC, and nitrogen washout were obtained before beginning the blood gas studies in nearly all the patients. Several patients were unable to cooperate sufficiently for satisfactory ventilatory studies.
A Cournand needle was inserted in the brachial arterv for serial sampling. All samples were drawn anaerobically in heparinized syringes and immediately placed in ice. Duplicate determination were checked within 2 0.5 mm PC*, + 1 mm Po2 and * .01 pH on a blood gas analyzer.? Patients tModel 113 Blood Gas Analyzer, Instrumentation Laboratory, Inc, Lexington, Mass. were all in a seated position, and following the baseline blood gas measurements, ultrasonic therapy was administered via an Ohio face tent with a DeVilbiss ultrasonic nebulizer: for a 20-minute period, utilizing a high setting of approximately four microliters per minute with isotonic saline as the nebulizing agent.
Specimens for blood gas studies were then drawn at 10-and 20-minute intervals during therapy and then 30 and 60 minutes after therapy had been discontinued. At the end of treatment the technician or the physician completed a questionnaire which was designed to assess subjective results of treatment and any side effects.
These blood gas studies were repeated in 15 of the 20 patients, with ultrasonic therapy being administered via a mouthpiece with intermittent positive pressure breathing (IPPB/U/air) at 15 cm of air pressure. Five patients were unable to tolerate the addition of IPPB and refused to proceed with the study. The initial form of therapy was alternated so that some patients were initially treated with ultrasonic ( U/air) and the others with IPPB/U/air.
For the purpose of this study, a change of 5 rnm or greater from the baseline Pa02 and PaCOz was considered significant. With ultrasonic treatment alone (U/air) a drop in PaOz ranging from -5 to -22 mm Hg occurred in all five patients in group 1 (Fig 1 ) , six of ten in group 2 (Fig 2) , and four of five in group 3 (Fig 3 ) . With ultrasonic therapy delivered by IPPB/U/air, a drop in PaOz ranging from -5 to -19 rnm Hg developed in three of five in group 1, three of seven in group 2, and one of three in group 3. With both U/ air and IPPB/ U/ air, the maximum decrease in PaOz first appeared occasionally at 10 minutes of treatment, usually by 20 minutes, and often following treatment. It should be noted that five patients in groups 2 and 3 either refused or were unable to complete IPPB/U/air therapy because of discomfort produced by the addition of IPPB, and blood gas studies could not be obtained.
A rise in Pam2 with a drop in pH accompanied the drop in PaOz with U/air therapy in two of the 20 patients studied and both occurred in patients with COLD. One was a patient in group 3 with a baseline Pamz of 49 and pH of 7.40. This patient developed a decrease in pH to 7.32 and rise in Pamz to 56 (Fig 4) . A decrease in Pam2 preceded the drop in PaOz in one patient each in group 1 and group 2 and was associated with a pH of 7.48 and 7.63, respectively. Figure 5 demonstrates the sequence of blood gas changes in the COLD patient in group 2 and shows a similar sequence with IPPB/U/air but without a decline in PaOz.
None of the 15 patients treated with IPPB/U/air $Model 800-880 DeVilbiss Ultrasonic Nebulizer, The Devil-FIGURE 1. Blood gas changes with ultrasonic/air and IPPB/ biss Company, Somerset, Penn.
ultrasonic/air in a group of ten control patients.
symptoms and only three had a drop in Pa02. The patients with COLD, ie groups 2 and 3, interrupted treatment four out of 15 times with U/air but seven out of ten times with IPPB/U/air. Interruption of inhalation therapy was for coughing, shortness of breath, choking, or fatigue and consisted of one to five brief episodes. These interruptions undoubtedly tended to allow restoration of blood gas abnormalities and reduced the degree and frequency of abnormalities.
Group 1 control patients tolerated ten separate treatment periods of 20 minutes each of U/air and IPPB/U/air therapy without interruption except for one episode, despite a significant drop in Pa02 during seven of the treatment periods.
In a separate study of four patients, four liters per minute nasal oxygen was administered along with ultrasonic therapy. Pa02 rose an average of 70 mm from the baseline with the PaOz ranging from 97.7 to 168 mm Hg during therapy. Three of the four patients had fewer symptoms with oxygen ( U / 0 2 ) than with U/air. showed a significant rise in Pam2, but three in group 1 and four in group 2 showed significant reductions. As expected, the serum pH reflected these changes, and five patients had a rise in pH of 7.5 or higher. Two were from group 1, one of whom developed a pH of 7.6. Three of these patients were from group 2, one of whom had a pH rise to 7.63 (Fig 6 ) , which was associated with a 15 mm decline in Pa02. None of the patients with baseline hypercapnia (group 3 ) showed any significant change in serum pH or Pama.
Symptoms of shortness of breath, headache, choking sensation, and chest pain occurred in ten of 15 patients with COLD treated with U/air, and of these, seven (70 percent) had a significant drop in Pa02. However, two of the five patients who did not complain of symptoms also had a drop in Pa02. None of the patients in the control group complained of Ulair therapy, yet all of the five patients had a drop in paO2. All ten COLD pa- viously reported by Pflug and co-workers8 of a decline in PaOz in a substantial percentage of COLD patients treated with ultrasonic nebulization, although different nebulization methods were used. We used normal saline, which may have caused a greater increase in airway resistance' than the 0.45 normal saline solution used by Pflug and colleagues,R but we also used a face tent rather than mouthpiece. Further evidence that symptoms in our COLD patients were due to an increase in airway resistance is the observation that our control patients had no symptoms, but they showed similar, if not even greater, declines in PaOz. In addition, increase in bronchial airway resistance was not observed by Cheney and Butler7 in their control patients and only in one of eight normals exposed to artificial fog by Abernethy.6 Furthermore, symptoms and blood gas changes in our study did not coincide consistently in COLD patients, especially when IPPB was added to ultrasonic therapy. Objective evaluation of the clinical value of inhalation therapy is difficult. A recent editorial9 succinctly described the dilemma of the increasing popularity of IPPB inhalational therapy despite conflicting favorable and unfavorable data for both physiologic and clinical studies following treatment. The same holds with the introduction of ultrasonic therapy. Wolfsdorf and associates1° utilizing labelled water calculated that at the most 80 milliliters per 24 hours was deposited in the lower respiratory tract through use of direct mouth tube breathing and far less through use of the face hood technique or tent. Ten or 20 minutes of treatment would indeed represent a very small quantity.
In addition, several studies clearly indicate that ultrasonic treatment produces an increase in bronchial airway resistance in patients with COLD or reactive bronchial trees.6-8sl"is is reversible
with bronchodilator therapy and is felt to be mainly The drop in PaOz with simple Ulair treatment seems to be the result of multiple factors. In two patients with COLD a significant rise in accompanying Paco2 and a drop in pH occurred, suggesting hypoventilation as the mechanism. In the remainder of the patients with COLD and also in group 1 patients, the Pacoz accompanying the decrease in Pa02 was unchanged or reduced. One must presume there were undesirable changes in ventilation-perfusion relationships as was suggested by Pflug and associates8 in their studies. They further noted that although bronchodilators reversed the bronchial airway resistance, they did not prevent the reduction in Pa02.
Another important factor contributing to a lower PaOa with ultrasonic treatment must be the increase in the workload of breathing caused by increased airway resistance in COLD patients. The coughing which is usually induced undoubtedly adds to the workload also. The addition of IPPB to ultrasonic treatment presumably should have resulted in a reduction of workload of breathing.11 Indeed, Pa02 was higher on the average with IPPB/U/air. However, this was the result of increased ventilation as shown by the mean decrease in Pacoz and rise in pH. In those who had a decreased PaOz there was a higher incidence of unaltered or depressed Pacop, again implying altered ventilation-perfusion relationships as the major mechanism.
Acute blood gas changes, such as hypoxia, respiratory acidosis, and especially respiratory alkalosis, carry the potential of triggering serious cardiac arrhythmias. In the past year we have seen two patients who had cardiac arrest during IPPB/U/02 therapy, which was being given as part of postoperative care. Bronchodilator drugs were not being administered in these two patients. Postmortem examination revealed moderately severe coronary atherosclerosis without myocardial infarction in one. In the other an autopsy was not obtained, but during resuscitative efforts ECG changes consistent with acute myocardial infarction were noted. The role inhalational therapy played in triggering the terminal episodes is speculative at the present.
Physicians who observe inhalational therapy being given to their patients or experience it themselves best appreciate why some patients have difficulty and discomfort. This is particularly true with IPPB/U. IPPB is most logically indicated in hypoventilating COLD patients but is most likely to cause discomfort in this very group. For technicians to struggle with patients and insist that they continue on inhalational therapy when they feel uncomfortable is probably hazardous. An overzealous physician or technician may indeed endanger a patient's life. Clinically, inhalational therapy seems to be useful in selected cases mainly in inducing production and expectoration of sputa, whether this is due to actual increased delivery of moisture to the lower bronchial tree or not. Before routine usage, one should consider the known hazards of nosocomial infections, as well as the effects on airway resistance and the blood gas changes. The airway resistance can be reversed by adding bronchodilators, and hypoxia by giving oxygen. However, other acute blood gas changes, such as respiratory alkalosis and respiratory acidosis may still occur.
Despite the 67 percent incidence of complaints of discomfort with ultrasonic nebulization, the curious paradox is that the majority of patients under direct questioning felt that the treatment was 'beneficial." This subjective improvement was judged by feel-ings of posttreatment improvement of breathing a n d easier expectoration of sputa. This w a s equally t r u e of those who had ultrasonic delivered b y IPPB, in w h o m the incidence of discomfort w a s even higher. How m u c h of the improvement w a s real and how much the influence of exposure to impressive and uncomfortable treatment is difficult to assess objectively. 197, 1963 
